Huberman Lab

Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson

303 snips
Sep 20, 2021
Guest
Matthew Johnson
In this enlightening discussion, Dr. Matthew Johnson, a leading researcher at Johns Hopkins, explores the groundbreaking potential of psychedelics like psilocybin and MDMA in treating mental health disorders. He details the clinical trials underway in his lab and explains the therapeutic framework necessary for success. Dr. Johnson also tackles common misconceptions, safety issues, and the evolving legal landscape surrounding psychedelics, emphasizing their transformative power in psychiatric medicine. His insights illuminate how these substances could redefine mental health care.
Ask episode
AI Snips
Chapters
Books
Transcript
Episode notes
ANECDOTE

Shift in Agency

  • A smoker realized he could simply decide not to smoke, like "flicking off a bike."
  • This illustrates the profound shift in agency psychedelics can facilitate.
ADVICE

Integration After the Session

  • After the session, participants write about their experience and discuss it the next day.
  • Supportive, non-structured therapy helps integrate these insights.
INSIGHT

Hallucinogen Persisting Perceptual Disorder

  • Hallucinogen persisting perceptual disorder (HPPD) is rare and might have neurological roots.
  • It's also seen in people who have never taken psychedelics.
Get the Snipd Podcast app to discover more snips from this episode
Get the app